Analyzing biological and molecular characteristics and genomic damage induced by exposure to asbestos

References

• Zurbriggen R, Capone L. [Pulmonary disease due to asbestos in steel industry workers]. Medicina (B Aires). 2013;73(3):224–230.23732197
   PubMed Web of Science ®Google Scholar
• Corfiati M, Scarselli A, Binazzi A, et al. Epidemiological patterns of asbestos exposure and spatial clusters of incident cases of malignant mesothelioma from the Italian national registry. BMC Cancer. 2015;15:286. doi:10.1186/s12885-015-1584-325885893
   PubMed Web of Science ®Google Scholar
• IARC. A review of human carcinogens. Part C: arsenic, metals, fibres, and dusts/IARC working group on the evaluation of carcinogenic risks to humans (2009: Lyon, France). International Agency for Research on Cancer. IARC Monogr Eval Carcinogenic Risks Humans. 100C 2012 Available from: http://monographs.iarc.fr/ENG/Monographs/vol100C/index.php. Accessed June 26, 2018.
   Google Scholar
• IARC. IARC Monographs on the Evaluation of Carcinogenic Risks to Humans, No. 100C. IARC Working Group on the Evaluation of Carcinogenic Risk to Humans. Lyon (FR): International Agency for Research on Cancer; 2012.
   Google Scholar
• IARC. Asbestos (chrysotile, amosite, crocidolite, tremolite, actinolite, and anthophyllite). IARC Monogr Eval Carcinog Risks Hum. 2012;100C:219–309. Available from: http://monographs.iarc.fr/ENG/Monographs/vol100C/index.php. Published 2012. Accessed 2018.
   Google Scholar
• Case BW, Abraham JL, Meeker G, Pooley FD, Pinkerton KE. Applying definitions of “asbestos” to environmental and “low-dose” exposure levels and health effects, particularly malignant mesothelioma. J Toxicol Environ Health B Crit Rev. 2011;14(1–4):3–39. doi:10.1080/10937404.2011.55604521534084
   PubMed Web of Science ®Google Scholar
• Mossman BT, Lippmann M, Hesterberg TW, Kelsey KT, Barchowsky A, Bonner JC. Pulmonary endpoints (lung carcinomas and asbestosis) following inhalation exposure to asbestos. J Toxicol Environ Health B Crit Rev. 2011;14(1–4):76–121. doi:10.1080/10937404.2011.55604721534086
   PubMed Web of Science ®Google Scholar
• Huang SX, Jaurand MC, Kamp DW, Whysner J, Hei TK. Role of mutagenicity in asbestos fiber-induced carcinogenicity and other diseases. J Toxicol Environ Health B Crit Rev. 2011;14(1–4):179–245. doi:10.1080/10937404.2011.55605121534089
   PubMed Web of Science ®Google Scholar
• Kamp DW. Asbestos-induced lung diseases: an update. Transl Res. 2009;153(4):143–152. doi:10.1016/j.trsl.2009.01.00419304273
   PubMed Web of Science ®Google Scholar
• Ossa A, Gomez D, Espinal C. Asbestos in Colombia: A silent enemy. Latreia. 2014;27(1):9.
   Google Scholar
• Liu G, Cheresh P, Kamp DW. Molecular basis of asbestos-induced lung disease. Annu Rev Pathol. 2013;8:161–187. doi:10.1146/annurev-pathol-020712-16394223347351
   PubMed Web of Science ®Google Scholar
• Yao S, DellaVentura G, Petibois C. Analytical characterization of cell-asbestos fiber interactions in lung pathogenesis. Anal Bioanal Chem. 2010;397(6):2079–2089. doi:10.1007/s00216-010-3773-x20490468
   PubMed Web of Science ®Google Scholar
• Organización Internacional del Trabajo. Enfermedades relacionadas con el amianto. Enciclopedia de salud y seguridad en el trabajo. 2001;1:57–71.
   Google Scholar
• Betti M, Casalone E, Ferrante D, et al. Germline mutations in DNA repair genes predispose asbestos-exposed patients to malignant pleural mesothelioma. Cancer Lett. 2017;405:38–45. doi:10.1016/j.canlet.2017.06.02828687356
   PubMed Web of Science ®Google Scholar
• Libbus BL, Illenye SA, Craighead JE. Induction of DNA strand breaks in cultured rat embryo cells by crocidolite asbestos as assessed by nick translation. Cancer Res. 1989;49(20):5713–5718.2790787
   PubMed Web of Science ®Google Scholar
• Mossman BT, Churg A. Mechanisms in the pathogenesis of asbestosis and silicosis. Am J Respir Crit Care Med. 1998;157(5 Pt 1):1666–1680. doi:10.1164/ajrccm.157.5.97071419603153
   PubMed Web of Science ®Google Scholar
• Federico A, Morgillo F, Tuccillo C, Ciardiello F, Loguercio C. Chronic inflammation and oxidative stress in human carcinogenesis. Int J Cancer. 2007;121(11):2381–2386. doi:10.1002/ijc.2319217893868
   PubMed Web of Science ®Google Scholar
• Kundu JK, Surh YJ. Inflammation: gearing the journey to cancer. Mutat Res. 2008;659(1–2):15–30. doi:10.1016/j.mrrev.2008.03.00218485806
   PubMed Web of Science ®Google Scholar
• Weitzman SA, Gordon LI. Inflammation and cancer: role of phagocyte-generated oxidants in carcinogenesis. Blood. 1990;76(4):655–663.2200535
   PubMed Web of Science ®Google Scholar
• Goldberg JL, Zanella CL, Janssen YM, et al. Novel cell imaging techniques show induction of apoptosis and proliferation in mesothelial cells by asbestos. Am J Respir Cell Mol Biol. 1997;17(3):265–271. doi:10.1165/ajrcmb.17.3.29919308911
   PubMed Web of Science ®Google Scholar
• Buder-Hoffmann S, Palmer C, Vacek P, Taatjes D, Mossman B. Different accumulation of activated extracellular signal-regulated kinases (ERK 1/2) and role in cell-cycle alterations by epidermal growth factor, hydrogen peroxide, or asbestos in pulmonary epithelial cells. Am J Respir Cell Mol Biol. 2001;24(4):405–413. doi:10.1165/ajrcmb.24.4.429011306433
   PubMed Web of Science ®Google Scholar
• Branchaud RM, Garant LJ, Kane AB. Pathogenesis of mesothelial reactions to asbestos fibers. Monocyte recruitment and macrophage activation. Pathobiology. 1993;61(3–4):154–163. doi:10.1159/0001637848216837
   PubMed Web of Science ®Google Scholar
• Kane AB. Mechanisms of mineral fibre carcinogenesis. IARC Sci Publ. 1996;140:11–34.9101315
   PubMedGoogle Scholar
• Kamp DW, Weitzman SA. The molecular basis of asbestos induced lung injury. Thorax. 1999;54(7):638–652.10377212
   PubMed Web of Science ®Google Scholar
• Manning CB, Vallyathan V, Mossman BT. Diseases caused by asbestos: mechanisms of injury and disease development. Int Immunopharmacol. 2002;2(2–3):191–200.11811924
   PubMedGoogle Scholar
• Shukla A, Gulumian M, Hei TK, Kamp D, Rahman Q, Mossman BT. Multiple roles of oxidants in the pathogenesis of asbestos-induced diseases. Free Radic Biol Med. 2003;34(9):1117–1129.12706492
   PubMed Web of Science ®Google Scholar
• Su B, Karin M. Mitogen-activated protein kinase cascades and regulation of gene expression. Curr Opin Immunol. 1996;8(3):402–411.8793994
   PubMed Web of Science ®Google Scholar
• Heintz NH, Janssen-Heininger YM, Mossman BT. Asbestos, lung cancers, and mesotheliomas: from molecular approaches to targeting tumor survival pathways. Am J Respir Cell Mol Biol. 2010;42(2):133–139. doi:10.1165/rcmb.2009-0206TR20068227
   PubMed Web of Science ®Google Scholar
• Janssen YM, Barchowsky A, Treadwell M, Driscoll KE, Mossman BT. Asbestos induces nuclear factor kappa B (NF-kappa B) DNA-binding activity and NF-kappa B-dependent gene expression in tracheal epithelial cells. Proc Natl Acad Sci USA. 1995;92(18):8458–8462. doi:10.1073/pnas.92.18.84587667311
   PubMed Web of Science ®Google Scholar
• Janssen-Heininger YM, Macara I, Mossman BT. Cooperativity between oxidants and tumor necrosis factor in the activation of nuclear factor (NF)-kappaB: requirement of Ras/mitogen-activated protein kinases in the activation of NF-kappaB by oxidants. Am J Respir Cell Mol Biol. 1999;20(5):942–952. doi:10.1165/ajrcmb.20.5.345210226064
   PubMed Web of Science ®Google Scholar
• Mathas S, Hinz M, Anagnostopoulos I, et al. Aberrantly expressed c-Jun and JunB are a hallmark of Hodgkin lymphoma cells, stimulate proliferation and synergize with NF-kappa B. Embo J. 2002;21(15):4104–4113.12145210
   PubMed Web of Science ®Google Scholar
• Zanella CL, Posada J, Tritton TR, Mossman BT. Asbestos causes stimulation of the extracellular signal-regulated kinase 1 mitogen-activated protein kinase cascade after phosphorylation of the epidermal growth factor receptor. Cancer Res. 1996;56(23):5334–5338.8968079
   PubMed Web of Science ®Google Scholar
• Manning CB, Cummins AB, Jung MW, et al. A mutant epidermal growth factor receptor targeted to lung epithelium inhibits asbestos-induced proliferation and proto-oncogene expression. Cancer Res. 2002;62(15):4169–4175.12154012
   PubMed Web of Science ®Google Scholar
• Zanella CL, Timblin CR, Cummins A, et al. Asbestos-induced phosphorylation of epidermal growth factor receptor is linked to c-fos and apoptosis. Am J Physiol. 1999;277(4 Pt 1):L684–L693. doi:10.1152/ajplung.1999.277.4.L68410516208
   PubMed Web of Science ®Google Scholar
• Dusinska M, Collins A, Kazimirova A, et al. Genotoxic effects of asbestos in humans. Mutat Res. 2004;553(1–2):91–102. doi:10.1016/j.mrfmmm.2004.06.02715288536
   PubMed Web of Science ®Google Scholar
• Testa JR, Cheung M, Pei J, et al. Germline BAP1 mutations predispose to malignant mesothelioma. Nat Genet. 2011;43(10):1022–1025. doi:10.1038/ng.91221874000
   PubMed Web of Science ®Google Scholar
• Betti M, Aspesi A, Biasi A, et al. CDKN2A and BAP1 germline mutations predispose to melanoma and mesothelioma. Cancer Lett. 2016;378(2):120–130. doi:10.1016/j.canlet.2016.05.01127181379
   PubMed Web of Science ®Google Scholar
• Baumann F, Flores E, Napolitano A, et al. Mesothelioma patients with germline BAP1 mutations have 7-fold improved long-term survival. Carcinogenesis. 2015;36(1):76–81. doi:10.1093/carcin/bgu22725380601
   PubMed Web of Science ®Google Scholar
• Carbone M, Flores EG, Emi M, et al. Combined genetic and genealogic studies uncover a large BAP1 cancer syndrome kindred tracing back nine generations to a common ancestor from the 1700s. PLoS Genet. 2015;11(12):e1005633. doi:10.1371/journal.pgen.100563326683624
   PubMed Web of Science ®Google Scholar
• Napolitano A, Pellegrini L, Dey A, et al. Minimal asbestos exposure in germline BAP1 heterozygous mice is associated with deregulated inflammatory response and increased risk of mesothelioma. Oncogene. 2016;35(15):1996–2002. doi:10.1038/onc.2015.24326119930
   PubMed Web of Science ®Google Scholar
• Ventii KH, Devi NS, Friedrich KL, et al. BRCA1-associated protein-1 is a tumor suppressor that requires deubiquitinating activity and nuclear localization. Cancer Res. 2008;68(17):6953–6962. doi:10.1158/0008-5472.CAN-08-036518757409
   PubMed Web of Science ®Google Scholar
• Assis LV, Isoldi MC. Overview of the biochemical and genetic processes in malignant mesothelioma. J Bras Pneumol. 2014;40(4):429–442.25210967
   PubMed Web of Science ®Google Scholar
• Nasu M, Emi M, Pastorino S, et al. High incidence of somatic BAP1 alterations in sporadic malignant mesothelioma. J Thorac Oncol. 2015;10(4):565–576. doi:10.1097/JTO.000000000000047125658628
   PubMed Web of Science ®Google Scholar
• Bott M, Brevet M, Taylor BS, et al. The nuclear deubiquitinase BAP1 is commonly inactivated by somatic mutations and 3p21.1 losses in malignant pleural mesothelioma. Nat Genet. 2011;43(7):668–672. doi:10.1038/ng.85521642991
   PubMed Web of Science ®Google Scholar
• McGregor SM, Dunning R, Hyjek E, Vigneswaran W, Husain AN, Krausz T. BAP1 facilitates diagnostic objectivity, classification, and prognostication in malignant pleural mesothelioma. Hum Pathol. 2015;46(11):1670–1678. doi:10.1016/j.humpath.2015.06.02426376834
   PubMed Web of Science ®Google Scholar
• Cigognetti M, Lonardi S, Fisogni S, et al. BAP1 (BRCA1-associated protein 1) is a highly specific marker for differentiating mesothelioma from reactive mesothelial proliferations. Mod Pathol. 2015;28(8):1043–1057. doi:10.1038/modpathol.2015.6526022455
   PubMed Web of Science ®Google Scholar
• Wong DW, Leung EL, So KK, et al. The EML4-ALK fusion gene is involved in various histologic types of lung cancers from nonsmokers with wild-type EGFR and KRAS. Cancer. 2009;115(8):1723–1733. doi:10.1002/cncr.2418119170230
   PubMed Web of Science ®Google Scholar
• Shaw AT, Engelman JA. ALK in lung cancer: past, present, and future. J Clin Oncol. 2013;31(8):1105–1111. doi:10.1200/JCO.2012.44.535323401436
   PubMed Web of Science ®Google Scholar
• Shaw AT, Yeap BY, Mino-Kenudson M, et al. Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK. J Clin Oncol. 2009;27(26):4247–4253. doi:10.1200/JCO.2009.22.699319667264
   PubMed Web of Science ®Google Scholar
• Ma PC, Maulik G, Christensen J, Salgia R. c-Met: structure, functions and potential for therapeutic inhibition. Cancer Metastasis Rev. 2003;22(4):309–325.12884908
   PubMed Web of Science ®Google Scholar
• Eder JP, Vande Woude GF, Boerner SA, LoRusso PM. Novel therapeutic inhibitors of the c-Met signaling pathway in cancer. Clin Cancer Res. 2009;15(7):2207–2214. doi:10.1158/1078-0432.CCR-08-130619318488
   PubMed Web of Science ®Google Scholar
• Carracedo A, Egervari K, Salido M, et al. FISH and immunohistochemical status of the hepatocyte growth factor receptor (c-Met) in 184 invasive breast tumors. Breast Cancer Res. 2009;11(2):402. doi:10.1186/bcr223919439036
   PubMed Web of Science ®Google Scholar
• Zucali PA, Ruiz MG, Giovannetti E, et al. Role of cMET expression in non-small-cell lung cancer patients treated with EGFR tyrosine kinase inhibitors. Ann Oncol. 2008;19(9):1605–1612. doi:10.1093/annonc/mdn24018467317
   PubMed Web of Science ®Google Scholar
• Jin Y, Sun PL, Kim H, et al. MET gene copy number gain is an independent poor prognostic marker in Korean stage I lung adenocarcinomas. Ann Surg Oncol. 2014;21(2):621–628. doi:10.1245/s10434-013-3355-124212721
   PubMed Web of Science ®Google Scholar
• Toschi L, Cappuzzo F. Clinical implications of MET gene copy number in lung cancer. Future Oncol. 2010;6(2):239–247. doi:10.2217/fon.09.16420146583
   PubMed Web of Science ®Google Scholar
• Engelman JA, Zejnullahu K, Mitsudomi T, et al. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science. 2007;316(5827):1039–1043. doi:10.1126/science.114147817463250
   PubMed Web of Science ®Google Scholar
• Sadiq AA, Salgia R. MET as a possible target for non-small-cell lung cancer. J Clin Oncol. 2013;31(8):1089–1096. doi:10.1200/JCO.2012.43.942223401458
   PubMed Web of Science ®Google Scholar
• Goldman JW, Laux I, Chai F, et al. Phase 1 dose-escalation trial evaluating the combination of the selective MET (mesenchymal-epithelial transition factor) inhibitor tivantinib (ARQ 197) plus erlotinib. Cancer. 2012;118(23):5903–5911. doi:10.1002/cncr.2757522605616
   PubMed Web of Science ®Google Scholar
• Hicks J. Biologic, cytogenetic, and molecular factors in mesothelial proliferations. Ultrastruct Pathol. 2006;30(1):19–30. doi:10.1080/0191312050031316816517467
   PubMed Web of Science ®Google Scholar
• Hesterberg TW, Barrett JC. Induction by asbestos fibers of anaphase abnormalities: mechanism for aneuploidy induction and possibly carcinogenesis. Carcinogenesis. 1985;6(3):473–475.3978760
   PubMed Web of Science ®Google Scholar
• Dopp E, Saedler J, Stopper H, Weiss DG, Schiffmann D. Mitotic disturbances and micronucleus induction in Syrian hamster embryo fibroblast cells caused by asbestos fibers. Environ Health Perspect. 1995;103(3):268–271. doi:10.1289/ehp.951032687768228
   PubMed Web of Science ®Google Scholar
• Ault JG, Cole RW, Jensen CG, Jensen LC, Bachert LA, Rieder CL. Behavior of crocidolite asbestos during mitosis in living vertebrate lung epithelial cells. Cancer Res. 1995;55(4):792–798.7850791
   PubMed Web of Science ®Google Scholar
• Tanaka K, Hirota T. Chromosomal instability: A common feature and a therapeutic target of cancer. Biochim Biophys Acta. 2016;1866(1):64–75. doi:10.1016/j.bbcan.2016.06.00227345585
   PubMed Web of Science ®Google Scholar
• Geigl JB, Obenauf AC, Schwarzbraun T, Speicher MR. Defining ‘chromosomal instability’. Trends Genet. 2008;24(2):64–69. doi:10.1016/j.tig.2007.11.00618192061
   PubMed Web of Science ®Google Scholar
• Gagos S, Irminger-Finger I. Chromosome instability in neoplasia: chaotic roots to continuous growth. Int J Biochem Cell Biol. 2005;37(5):1014–1033. doi:10.1016/j.biocel.2005.01.00315743675
   PubMed Web of Science ®Google Scholar
• Dayal J, Albergant L, Newman T, South A. Quantitation of multiclonality in control and drug-treated tumour populations using high-throughput analysis of karyotypic heterogeneity. Converg Sci Phys Oncol. 2015;1:2. doi:10.1088/2057-1739/1/2/025001
   Google Scholar
• Marini V, Michelazzi L, Cioe A, Fucile C, Spigno F, Robbiano L. Exposure to asbestos: correlation between blood levels of mesothelin and frequency of micronuclei in peripheral blood lymphocytes. Mutat Res. 2011;721(1):114–117. doi:10.1016/j.mrgentox.2010.12.01421238604
   PubMed Web of Science ®Google Scholar
• Horska A, Kazimirova A, Barancokova M, Wsolova L, Tulinska J, Dusinska M. Genetic predisposition and health effect of occupational exposure to asbestos. Neuro Endocrinol Lett. 2006;27(Suppl 2):100–103.17159790
   PubMedGoogle Scholar
• Kawami M, Ebihara I. Cytogenetic damage and cell-mediated immunity in pneumoconiosis. J Environ Pathol Toxicol Oncol. 2000;19(1–2):103–108.10905516
   PubMedGoogle Scholar
• Govercin M, Tomatir AG, Evyapan F, Acikbas I, Coskun G, Akdag B. Elevated micronucleus frequencies in patients with pleural plaque secondary to environmental exposure to asbestos. Genet Mol Res. 2014;13(1):598–604. doi:10.4238/2014.January.28.524615025
   PubMed Web of Science ®Google Scholar
• Donmez-Altuntas H, Baran M, Oymak FS, et al. Investigation of micronucleus frequencies in lymphocytes of inhabitants environmentally exposed to chrysotile asbestos. Int J Environ Health Res. 2007;17(1):45–51. doi:10.1080/0960312060112423117365079
   PubMed Web of Science ®Google Scholar
• Bolognesi C, Martini F, Tognon M, et al. A molecular epidemiology case control study on pleural malignant mesothelioma. Cancer Epidemiol Biomarkers Prev. 2005;14(7):1741–1746. doi:10.1158/1055-9965.EPI-04-090316030111
   PubMed Web of Science ®Google Scholar
• Bueno R, Stawiski EW, Goldstein LD, et al. Comprehensive genomic analysis of malignant pleural mesothelioma identifies recurrent mutations, gene fusions and splicing alterations. Nat Genet. 2016;48(4):407–416. doi:10.1038/ng.352026928227
   PubMed Web of Science ®Google Scholar
• Singhi AD, Krasinskas AM, Choudry HA, et al. The prognostic significance of BAP1, NF2, and CDKN2A in malignant peritoneal mesothelioma. Mod Pathol. 2016;29(1):14–24. doi:10.1038/modpathol.2015.12126493618
   PubMed Web of Science ®Google Scholar
• Jean D, Daubriac J, Le Pimpec-Barthes F, Galateau-Salle F, Jaurand MC. Molecular changes in mesothelioma with an impact on prognosis and treatment. Arch Pathol Lab Med. 2012;136(3):277–293. doi:10.5858/arpa.2011-0215-RA22372904
   PubMed Web of Science ®Google Scholar
• Sekido Y, Pass HI, Bader S, et al. Neurofibromatosis type 2 (NF2) gene is somatically mutated in mesothelioma but not in lung cancer. Cancer Res. 1995;55(6):1227–1231.7882313
   PubMed Web of Science ®Google Scholar
• Hirao T, Bueno R, Chen CJ, Gordon GJ, Heilig E, Kelsey KT. Alterations of the p16(INK4) locus in human malignant mesothelial tumors. Carcinogenesis. 2002;23(7):1127–1130.12117769
   PubMed Web of Science ®Google Scholar
• Guo G, Chmielecki J, Goparaju C, et al. Whole-exome sequencing reveals frequent genetic alterations in BAP1, NF2, CDKN2A, and CUL1 in malignant pleural mesothelioma. Cancer Res. 2015;75(2):264–269. doi:10.1158/0008-5472.CAN-14-100825488749
   PubMed Web of Science ®Google Scholar
• Krismann M, Muller KM, Jaworska M, Johnen G. Molecular cytogenetic differences between histological subtypes of malignant mesotheliomas: DNA cytometry and comparative genomic hybridization of 90 cases. J Pathol. 2002;197(3):363–371. doi:10.1002/path.112812115883
   PubMed Web of Science ®Google Scholar
• Nymark P, Wikman H, Hienonen-Kempas T, Anttila S. Molecular and genetic changes in asbestos-related lung cancer. Cancer Lett. 2008;265(1):1–15. doi:10.1016/j.canlet.2008.02.04318364247
   PubMed Web of Science ®Google Scholar
• Nelson HH, Wiencke JK, Gunn L, Wain JC, Christiani DC, Kelsey KT. Chromosome 3p14 alterations in lung cancer: evidence that FHIT exon deletion is a target of tobacco carcinogens and asbestos. Cancer Res. 1998;58(9):1804–1807.9581816
   PubMed Web of Science ®Google Scholar
• Tiainen M, Tammilehto L, Rautonen J, Tuomi T, Mattson K, Knuutila S. Chromosomal abnormalities and their correlations with asbestos exposure and survival in patients with mesothelioma. Br J Cancer. 1989;60(4):618–626.2803935
   PubMed Web of Science ®Google Scholar
• Tammilehto L, Tuomi T, Tiainen M, et al. Malignant mesothelioma: clinical characteristics, asbestos mineralogy and chromosomal abnormalities of 41 patients. Eur J Cancer. 1992;28A(8–9):1373–1379.1325175
   PubMed Web of Science ®Google Scholar
• Jean D, Thomas E, Manie E, et al. Syntenic relationships between genomic profiles of fiber-induced murine and human malignant mesothelioma. Am J Pathol. 2011;178(2):881–894. doi:10.1016/j.ajpath.2010.10.03921281820
   PubMed Web of Science ®Google Scholar
• Chirac P, Maillet D, Lepretre F, et al. Genomic copy number alterations in 33 malignant peritoneal mesothelioma analyzed by comparative genomic hybridization array. Hum Pathol. 2016;55:72–82. doi:10.1016/j.humpath.2016.04.01527184482
   PubMed Web of Science ®Google Scholar
• Cui Y, Ma J, Ye W, et al. Chrysotile and rock wool fibers induce chromosome aberrations and DNA damage in V79 lung fibroblast cells. Environ Sci Pollut Res Int. 2018;25(23):22328–22333. doi:10.1007/s11356-017-9403-928685333
   PubMed Web of Science ®Google Scholar
• IARC working group on the evaluation of carcinogenic risks to humans: Asbestos. International Agency for Research on Cancer. 1987;Supplement 7:106–116.
   Google Scholar
• Algranti EM. S Parkes’ Occupational Lung Disorders. Fourth ed. London: Taylor and Francis; 2016.
   Google Scholar
• Roggli VL, Gibbs AR, Attanoos R, et al. Pathology of asbestosis- An update of the diagnostic criteria: report of the asbestosis committee of the college of american pathologists and pulmonary pathology society. Arch Pathol Lab Med. 2010;134(3):462–480. doi:10.1043/1543-2165-134.3.46220196674
   PubMed Web of Science ®Google Scholar
• American Thoracic S. Diagnosis and initial management of nonmalignant diseases related to asbestos. Am J Respir Crit Care Med. 2004;170(6):691–715. doi:10.1164/rccm.200310-1436ST15355871
   PubMed Web of Science ®Google Scholar
• Montanaro F, Bray F, Gennaro V, et al. Pleural mesothelioma incidence in Europe: evidence of some deceleration in the increasing trends. Cancer Causes Control. 2003;14(8):791–803.14674744
   PubMed Web of Science ®Google Scholar
• Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018. doi:10.3322/caac.21492
   PubMed Web of Science ®Google Scholar
• Nelson HH, Kelsey KT. The molecular epidemiology of asbestos and tobacco in lung cancer. Oncogene. 2002;21(48):7284–7288. doi:10.1038/sj.onc.120580412379872
   PubMed Web of Science ®Google Scholar
• Kjuus H, Skjaerven R, Langard S, Lien JT, Aamodt T. A case-referent study of lung cancer, occupational exposures and smoking. II. Role of asbestos exposure. Scand J Work Environ Health. 1986;12(3):203–209.3749834
   PubMed Web of Science ®Google Scholar
• Carbone M, Ly BH, Dodson RF, et al. Malignant mesothelioma: facts, myths, and hypotheses. J Cell Physiol. 2012;227(1):44–58. doi:10.1002/jcp.2272421412769
   PubMed Web of Science ®Google Scholar
• Goldberg M, Luce D. The health impact of nonoccupational exposure to asbestos: what do we know? Eur J Cancer Prev. 2009;18(6):489–503. doi:10.1097/CEJ.0b013e32832f9bee19617842
   PubMed Web of Science ®Google Scholar
• Damhuis RA, Khakwani A, De Schutter H, Rich AL, Burgers JA, van Meerbeeck JP. Treatment patterns and survival analysis in 9014 patients with malignant pleural mesothelioma from Belgium, the Netherlands and England. Lung Cancer. 2015;89(2):212–217. doi:10.1016/j.lungcan.2015.05.01426044908
   PubMed Web of Science ®Google Scholar
• Vogelzang NJ, Rusthoven JJ, Symanowski J, et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol. 2003;21(14):2636–2644. doi:10.1200/JCO.2003.11.13612860938
   PubMed Web of Science ®Google Scholar
• Donovan EP, Donovan BL, McKinley MA, Cowan DM, Paustenbach DJ. Evaluation of take home (para-occupational) exposure to asbestos and disease: a review of the literature. Crit Rev Toxicol. 2012;42(9):703–731. doi:10.3109/10408444.2012.70982122913651
   PubMed Web of Science ®Google Scholar
• Espinosa Munoz E, Ramirez Ocana D, Gutierrez Cardo AL. Malignant pleural mesothelioma in a young adult with no known exposure to asbestos. Arch Bronconeumol. 2016;52(12):615–616. doi:10.1016/j.arbres.2016.03.00827156205
   PubMed Web of Science ®Google Scholar
• Carmona E, María R. Asbestosis and malignant pleural mesothelioma. Revista De La Facultad De Medicina (México). 2013;52(2):5–17.
   Google Scholar
• Lo Iacono M, Monica V, Righi L, et al. Targeted next-generation sequencing of cancer genes in advanced stage malignant pleural mesothelioma: a retrospective study. J Thorac Oncol. 2015;10(3):492–499. doi:10.1097/JTO.000000000000043625514803
   PubMed Web of Science ®Google Scholar
• Tian L, Zeng R, Wang X, et al. Prognostic significance of soluble mesothelin in malignant pleural mesothelioma: a meta-analysis. Oncotarget. 2017;8(28):46425–46435. doi:10.18632/oncotarget.1743628507279
   PubMedGoogle Scholar
• Creaney J, Robinson BW. Detection of malignant mesothelioma in asbestos-exposed individuals: the potential role of soluble mesothelin-related protein. Hematol Oncol Clin North Am. 2005;19(6):1025–1040. doi:10.1016/j.hoc.2005.09.00716325121
   PubMed Web of Science ®Google Scholar
• Creaney J, Yeoman D, Demelker Y, et al. Comparison of osteopontin, megakaryocyte potentiating factor, and mesothelin proteins as markers in the serum of patients with malignant mesothelioma. J Thorac Oncol. 2008;3(8):851–857. doi:10.1097/JTO.0b013e318180477b18670302
   PubMed Web of Science ®Google Scholar
• Pass HI, Levin SM, Harbut MR, et al. Fibulin-3 as a blood and effusion biomarker for pleural mesothelioma. N Engl J Med. 2012;367(15):1417–1427. doi:10.1056/NEJMoa111505023050525
   PubMed Web of Science ®Google Scholar
• Pei D, Li Y, Liu X, et al. Diagnostic and prognostic utilities of humoral fibulin-3 in malignant pleural mesothelioma: evidence from a meta-analysis. Oncotarget. 2017;8(8):13030–13038. doi:10.18632/oncotarget.1471228103581
   PubMedGoogle Scholar
• Yang H, Rivera Z, Jube S, et al. Programmed necrosis induced by asbestos in human mesothelial cells causes high-mobility group box 1 protein release and resultant inflammation. Proc Natl Acad Sci US A. 2010;107(28):12611–12616. doi:10.1073/pnas.1006542107
   PubMed Web of Science ®Google Scholar
• Lopez-Campos JL, Sanchez Silva R, Gomez Izquierdo L, et al. Overexpression of Aquaporin-1 in lung adenocarcinomas and pleural mesotheliomas. Histol Histopathol. 2011;26(4):451–459. doi:10.14670/HH-26.45121360438
   PubMed Web of Science ®Google Scholar
• Begin R, Martel M, Desmarais Y, et al. Fibronectin and procollagen 3 levels in bronchoalveolar lavage of asbestos-exposed human subjects and sheep. Chest. 1986;89(2):237–243.3943384
   PubMed Web of Science ®Google Scholar
• Ilavska S, Jahnova E, Tulinska J, et al. Immunological monitoring in workers occupationally exposed to asbestos. Toxicology. 2005;206(2):299–308. doi:10.1016/j.tox.2004.09.00415588921
   PubMed Web of Science ®Google Scholar
• Tulinska J, Jahnova E, Dusinska M, et al. Immunomodulatory effects of mineral fibres in occupationally exposed workers. Mutat Res. 2004;553(1–2):111–124. doi:10.1016/j.mrfmmm.2004.06.03015288538
   PubMed Web of Science ®Google Scholar
• Ledda C, Senia P, Rapisarda V. Biomarkers for early diagnosis and prognosis of malignant pleural mesothelioma: the quest goes on. Cancers (Basel). 2018;10:6. doi:10.3390/cancers10110400
   PubMed Web of Science ®Google Scholar
• Ledda C, Rapisarda V. Malignant pleural mesothelioma: the need to move from research to clinical practice. Arch Med Res. 2016;47(5):407. doi:10.1016/j.arcmed.2016.08.00927751377
   PubMed Web of Science ®Google Scholar
• Weber DG, Johnen G, Bryk O, Jockel KH, Bruning T. Identification of miRNA-103 in the cellular fraction of human peripheral blood as a potential biomarker for malignant mesothelioma–a pilot study. PLoS One. 2012;7(1):e30221. doi:10.1371/journal.pone.003022122253921
   PubMed Web of Science ®Google Scholar
• Mairinger FD, Werner R, Flom E, et al. miRNA regulation is important for DNA damage repair and recognition in malignant pleural mesothelioma. Virchows Arch. 2017;470(6):627–637. doi:10.1007/s00428-017-2133-z28466156
   PubMed Web of Science ®Google Scholar
• Gayosso-Gomez LV, Zarraga-Granados G, Paredes-Garcia P, et al. Identification of circulating miRNAs profiles that distinguish malignant pleural mesothelioma from lung adenocarcinoma. Excli J. 2014;13:740–750.26417297
   PubMed Web of Science ®Google Scholar
• Cavalleri T, Angelici L, Favero C, et al. Plasmatic extracellular vesicle microRNAs in malignant pleural mesothelioma and asbestos-exposed subjects suggest a 2-miRNA signature as potential biomarker of disease. PLoS One. 2017;12(5):e0176680. doi:10.1371/journal.pone.017668028472171
   PubMed Web of Science ®Google Scholar
• Flanagan DM. Asbestos - 2016 [Advance Release]. Washington, DC: U.S. Geological survey minerals yearbook; 2018.
   Google Scholar
• Social MdlP. Plan nacional para la prevención de la silicosis, la neumoconiosis de los mineros de carbón y la asbestosiS. Available from: http://www.academia.edu/27651303/plan_nacional_para_la_prevenci%c3%93n_de_la_silicosis_la_neumoconiosis_de_los_mineros_de_carb%c3%93n_y_la_asbestosis. Published 2010 Accessed 12, 2018.
   Google Scholar
• Pylkkanen L, Sainio M, Ollikainen T, et al. Concurrent LOH at multiple loci in human malignant mesothelioma with preferential loss of NF2 gene region. Oncol Rep. 2002;9(5):955–959.12168054
   PubMed Web of Science ®Google Scholar
• Pylkkanen L, Wolff H, Stjernvall T, Knuuttila A, Anttila S, Husgafvel-Pursiainen K. Reduced Fhit protein expression in human malignant mesothelioma. Virchows Arch. 2004;444(1):43–48. doi:10.1007/s00428-003-0902-314569398
   PubMed Web of Science ®Google Scholar
• Thurneysen C, Opitz I, Kurtz S, Weder W, Stahel RA, Felley-Bosco E. Functional inactivation of NF2/merlin in human mesothelioma. Lung Cancer. 2009;64(2):140–147. doi:10.1016/j.lungcan.2008.08.01418835652
   PubMed Web of Science ®Google Scholar
• Napolitano A, Antoine DJ, Pellegrini L, et al. HMGB1 and its hyperacetylated isoform are sensitive and specific serum biomarkers to detect asbestos exposure and to identify mesothelioma patients. Clin Cancer Res. 2016;22(12):3087–3096. doi:10.1158/1078-0432.CCR-15-113026733616
   PubMed Web of Science ®Google Scholar